We performed a pilot trial of subcutaneous treprostinil for the treatment of digital ulcers in scleroderma. Of the 5 patients completing therapy, ulcer size significantly decreased and no new ulcers occurred on continuous therapy. Although effective, the high rate of injection site reactions may limit the utility of this therapy.
View details for DOI 10.1016/j.jaad.2006.02.004
View details for Web of Science ID 000237119600019
View details for PubMedID 16635673